F. R.
- Country
- The Netherlands
- Department
- Medische Oncologie
Research Overview
- Adjuvant Pembrolizumab Versus Capecitabine or Olaparib in Patients with Early-Stage Triple-Negative Breast Cancer with Residual Disease Following Neoadjuvant Therapy
- Evaluation of Trastuzumab and Pertuzumab Addition to Neoadjuvant Chemoradiation in Resectable HER2-Positive Esophageal Adenocarcinoma
- Evaluation of Metformin Hydrochloride as a Metabolic Intervention in Oesophageal Adenocarcinoma to Enhance Neoadjuvant Chemoradiotherapy Response
Data & Insights
Has run more than one trial at 38 of 73 partner sites.
Specializations
Gastrointestinal Oncology
This investigator specializes in treating advanced esophagogastric cancer, with particular focus on developing therapeutic strategies for metastatic and locally advanced cases.
- Esophageal Cancer Treatment
- Gastric Cancer Management
- Advanced Disease Therapeutics
Their research interests encompass innovative treatment approaches using liposomal formulations and platinum-based therapies for gastrointestinal malignancies.
Novel Treatment Approaches
The investigator focuses on evaluating various therapeutic combinations in first-line treatment settings, particularly exploring the effectiveness of different chemotherapy regimens.
- Combination Therapy Development
- Treatment Response Assessment
- Progression Monitoring
Their work includes investigating disease progression patterns and treatment outcomes in gastrointestinal oncology.
Clinical Outcomes Research
The investigator examines survival metrics and treatment-related effects, with particular attention to neurotoxicity assessment in cancer therapeutics.
- Progression-Free Survival Analysis
- Side Effect Management
- Treatment Efficacy Evaluation
Their research encompasses comprehensive evaluation of treatment outcomes in advanced gastrointestinal cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.